Free Trial
→ Elon will prove them wrong again (From Paradigm Press) (Ad)tc pixel
NASDAQ:TAOX

Synaptogenix Q3 2025 Earnings Results & Report

Synaptogenix logo
$3.50 -0.18 (-4.76%)
As of 02:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Synaptogenix reported Q3 2025 earnings on November 14, 2025. The company reported EPS of -$1.56, while revenue was $2.41 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens

Synaptogenix EPS Results

Actual EPS
-$1.56
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
$2.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Synaptogenix Q3 2025 Earnings FAQ

Synaptogenix (NASDAQ:TAOX) reported earnings of -$1.56 per share for Q3 2025. The report was announced on Friday, November 14, 2025.

Synaptogenix reported revenue of $2.41 million for Q3 2025.

Synaptogenix Earnings Headlines

Synaptogenix (NASDAQ:TAOX) & Otsuka (OTCMKTS:OTSKY) Critical Contrast
October 12 at 4:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109745
Comparing Innoviva (NASDAQ:INVA) and Synaptogenix (NASDAQ:TAOX)
October 11 at 10:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31108255
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
October 14 at 1:00 AM  |  Behind the Markets (Ad)
Synaptogenix (NASDAQ:TAOX) Cut to Sell at Wall Street Zen
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083604
TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor
July 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-appoints-bittensor-investor-and-author-mark-jeffrey-as-advisor-302820337.html
TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-set-to-join-the-russell-microcap-index-as-a-leading-public-gateway-to-decentralized-ai-302801330.html
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases and disorders involving memory and cognitive function. The company has primarily investigated treatments designed to support synaptic function and neuronal health.

Its lead research program has centered on bryostatin-1, a naturally derived compound being studied for its potential to activate protein kinase C epsilon and improve cognitive function in patients with Alzheimer’s disease. Synaptogenix has also explored potential applications of its technology in other neurological conditions, although its programs remain investigational and the company does not have an established portfolio of approved commercial products.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as it refined its focus on neurodegenerative disease research. Public information identifies Synaptogenix with the Nasdaq ticker SNPX; the ticker symbol TAOX appears to refer to a different issuer. Accordingly, the company and symbol provided should be independently verified before use.

View Synaptogenix Profile
Earnings Tools